Cargando…

Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports

BACKGROUND: Schizophrenia and bipolar disorder are severe mental illnesses which are highly prevalent worldwide. Risperidone and Paliperidone are treatments for either illnesses, but their efficacy compared to other antipsychotics and growing reports of hormonal imbalances continue to raise concerns...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hodkinson, Alexander, Heneghan, Carl, Mahtani, Kamal R., Kontopantelis, Evangelos, Panagioti, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386072/ https://www.ncbi.nlm.nih.gov/pubmed/34429113 http://dx.doi.org/10.1186/s12916-021-02062-w

Ejemplares similares

Comparative Pharmacology of Risperidone and Paliperidone
por: Corena-McLeod, Maria
Publicado: (2015)

Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
por: Turkoz, Ibrahim, et al.
Publicado: (2011)

S56. SWITCHING FROM RISPERIDONE TO PALIPERIDONE PALMITATE IN SCHIZOPHRENIA: CHANGES IN COGNITIVE FUNCTION
por: Tost Bonet, Meritxell, et al.
Publicado: (2020)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
por: Patel, Charmi, et al.
Publicado: (2019)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs, Larry, et al.
Publicado: (2013)

The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection
por: Stump, Trevor A., et al.
Publicado: (2021)

Audit on prolactin monitoring for patients on oral risperidone, intramuscular risperidone, and intramuscular paliperidone
por: Bader, Mohamed
Publicado: (2021)

Effects of Risperidone and Paliperidone on Brain-Derived Neurotrophic Factor and N400 in First-Episode Schizophrenia
por: Wu, Rong-Qin, et al.
Publicado: (2018)

Determination of Plasma Concentration Reference Ranges for Risperidone and Paliperidone
por: Korell, J, et al.
Publicado: (2017)

PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone
por: Mathews, Maju, et al.
Publicado: (2016)

Why clinical trial outcomes fail to translate into benefits for patients
por: Heneghan, Carl, et al.
Publicado: (2017)

Evidence based administration of risperidone and paliperidone for the treating conduct disorder
por: Ghanizadeh, Ahmad
Publicado: (2013)

Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety
por: Zhao, Mingjun, et al.
Publicado: (2023)

Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia
por: Bishop, Jeffrey R, et al.
Publicado: (2008)

Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis
por: Patel, Charmi, et al.
Publicado: (2020)

RISPERIDONE IN SCHIZOPHRENIA
por: Agashe, Mohan, et al.
Publicado: (1999)

RISPERIDONE IN SCHIZOPHRENIA
por: Kumar, P.N. Suresh
Publicado: (1999)

Risperidone in the treatment of bipolar mania
por: Sajatovic, Martha, et al.
Publicado: (2006)

Dosing strategies for switching from oral risperidone to paliperidone palmitate: Effects on clinical outcomes
por: Hsia, Stephanie L., et al.
Publicado: (2018)

Treatment of bipolar mania with paliperidone extended-release
por: Kotorki, Paraskevi, et al.
Publicado: (2010)

Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics
por: Schreiner, A, et al.
Publicado: (2015)

Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial
por: Takekita, Yoshiteru, et al.
Publicado: (2016)

Tachycardia during Treatment with Risperidone and Paliperidone Palmitate in a Patient without Previous Cardiovascular Disease
por: Orlins, Zachary, et al.
Publicado: (2021)

Applications of simple and accessible methods for meta-analysis involving rare events: A simulation study
por: Hodkinson, Alexander, et al.
Publicado: (2021)

Self-management interventions to reduce healthcare use and improve quality of life among patients with asthma: systematic review and network meta-analysis
por: Hodkinson, Alexander, et al.
Publicado: (2020)

Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis
por: Hodkinson, Alexander, et al.
Publicado: (2022)

RISPERIDONE IN INDIAN PATIENTS WITH SCHIZOPHRENIA
por: Duggal, Harpreet S., et al.
Publicado: (1999)

RISPERIDONE IN INDIAN PATIENTS WITH SCHIZOPHRENIA
por: Agarwal, A.K., et al.
Publicado: (1998)

The role of paliperidone extended release for the treatment of bipolar disorder
por: Marino, Jehan, et al.
Publicado: (2012)

A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models
por: Boyda, Heidi N., et al.
Publicado: (2021)

GPs’ use and understanding of the benefits and harms of treatments for long-term conditions: a qualitative interview study
por: Treadwell, Julian, et al.
Publicado: (2021)

Paliperidone: the evidence of its therapeutic value in schizophrenia
por: Kantrowitz, Joshua, et al.
Publicado: (2007)

Once-monthly paliperidone injection for the treatment of schizophrenia
por: Bishara, Delia
Publicado: (2010)

PM394. The outcome of paliperidone palmitate in schizophrenia
por: Ju, Po-Chung
Publicado: (2016)

Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
por: Gao, Keming, et al.
Publicado: (2013)

Accelerometer- and Pedometer-Based Physical Activity Interventions Among Adults With Cardiometabolic Conditions: A Systematic Review and Meta-analysis
por: Hodkinson, Alexander, et al.
Publicado: (2019)

Interventions Using Wearable Physical Activity Trackers Among Adults With Cardiometabolic Conditions: A Systematic Review and Meta-analysis
por: Hodkinson, Alexander, et al.
Publicado: (2021)

The potential impact of Brexit and immigration policies on the GP workforce in England: a cross-sectional observational study of GP qualification region and the characteristics of the areas and population they served in September 2016
por: Esmail, Aneez, et al.
Publicado: (2017)

Pharmacokinetic-Pharmacodynamic Modeling of the D(2) and 5-HT(2A) Receptor Occupancy of Risperidone and Paliperidone in Rats
por: Kozielska, Magdalena, et al.
Publicado: (2012)

Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole
por: Remmerie, Bart, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5d66pdtvtliinltg1rd8ma2ii6